TNGX Tango Therapeutics, Inc.
Tango Therapeutics, Inc. (TNGX) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.33 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.4% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Tango Therapeutics, Inc.
Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.
Sector
Healthcare
Industry
Biotechnology